



Zedira to present at BioEurope® 2014: License opportunities in celiac disease and anticoagulation

Zedira presents on Tuesday, November 4, 14:00 at the Session "Focus on Hessen" | Level 1 | Room Transparenz 2. Feel free to contact us for a one-to-one meeting.

The BIO-Europe® 2014 is taking place in Frankfurt on November 3–5, 2014 at Portalhaus Messe Frankfurt, Germany.

Meet Zedira to discuss license opportunities in celiac disease (outside Europe) or to join our drug discovery project for "safe anticoagulation".

About Zedira

The Darmstadt-based biopharmaceutical company focuses on the transglutaminase family of enzymes. Based on its patented family of low-molecular weight transglutaminase blockers, Zedira is establishing an active ingredient pipeline. Drug candidate ZED1227 for the indication celiac disease in Europe has been successfully out licensed to Dr. Falk Pharma in 2011. As an area of secondary indication Zedira is working on new approaches to thrombosis prophylaxis. The company develops, produces and markets products for research and development as well as for diagnostics.

This communication is published by:

Zedira GmbH

Roesslerstr. 83
64293 Darmstadt
Germany

Phone: +49 6151 3251-00
Fax: +49 6151 3251-19

Web: www.zedira.com
E-mail: contact@zedira.com

© 2014, Zedira GmbH